Found 33 Lymphoma trials
A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.
This study plans to treat subjects with pembrolizumab by infusion in combination with radiation therapy to see if the combination is an effective treatment for relapsed/refractory non-Hodgkin lymphoma. Radiation therapy is commonly used to treat relapsed/refractory non-Hodgkin lymphoma. Although pembrolizumab is FDA-approved for some cancers, including Hodgkin lymphoma, it is …
Please refer to Protocol 17-054, Section 2.0 (Objectives and Scientific Aims) Please refer to Protocol 17-054, Section 14.0 (Biostatistics, Primary Endpoints) Please refer to Protocol 17-054, Section 14.0 (Biostatistics, Secondary Endpoints)
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Please refer to Protocol Section 3.1 (Primary Objectives, Endpoints & Hypotheses). Please refer to Protocol Section 3.1 Primary Objectives, Endpoints & Hypotheses. Please refer to Protocol Section 3.2 (Secondary Objectives and Endpoints).
Please refer to Protocol Section 2 (Objective and Endpoints). Please refer to Protocol Section 2 (Objective and Endpoints). Please refer to Protocol Section 2 (Objective and Endpoints).
Phase 2 trial studying the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in treating patients with mantle cell lymphoma that relapsed or does not respond to treatment (refractory). We would like to rely on Advarra as the IRB of record for this study.
The purpose of this study is to evaluate the safety, recommended dose, antitumor activity, and pharmacokinetics of JCAR017 in subjects with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The safety of JCAR017 in subjects who are receiving concurrent ibrutinib will also be evaluated.
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment …
